Module 1: Regulatory Considerations for the Development of CNS/Neurology Therapeutics

Recorded On: 02/15/2024

image
image


According to 21 CFR Part 312.23 (a)(8) of the US regulations, sufficient information derived from nonclinical pharmacology and toxicology studies is needed in order to support the decision that a clinical trial in human subjects is reasonably safe and scientifically feasible to conduct. The data resulting from the nonclinical studies should support scientific proof-of-principle and safety for the administration of the investigational product in the specified clinical population. In addition, nonclinical studies help guide the design of certain elements of a clinical trial. The development of cell and gene therapies for neurological indications over recent decades has demonstrated the potential clinical benefits of these therapies for this heterogeneous group of disorders. However, there remain significant questions, including the risks associated with these products that are not understood. Thus, a comprehensive nonclinical characterization of novel cell and gene therapy products and their associated risks are critical for the safe conduct of future clinical trials. This presentation will provide a general overview of the Center for Biologics Evaluation and Research’s Office of Therapeutic Products (OTP), the existing regulatory framework, including avenues for interactive communications, and resources to guide stakeholders in the nonclinical assessment of the safety and activity of cell and gene therapy products for neurological indications.

Mondona McCann, PhD

Mondona McCann, PhD

Pharmacology/Toxicology Reviewer

US FDA

Dr. Mondona McCann is a Pharmacology/Toxicology reviewer in the U.S. Food and Drug Administration (FDA)’s Center for Biologics Evaluation and Research (CBER)’s Office of Therapeutic Products. She received her PhD in neuroscience from Georgetown University; her thesis research investigated the impact of organochlorine environmental toxicants on astrocytic function and metabolism. Following her graduate studies, Dr. McCann completed her post-doctoral training at the FDA where she conducted research on the efficacy and safety of IL13Rα2 CAR T cell therapy for glioblastoma and pancreatic cancer. At the completion of her fellowship, Dr. McCann joined the Office of Pharmacology and Toxicology, where she now focuses on the review of nonclinical toxicology and pharmacology data to support the safety of a variety of products including cell and gene therapies, tissue engineered products, and tumor vaccines.

Key:

Complete
Failed
Available
Locked
Module 1 Regulatory Considerations for the Development of CNS/Neurology Therapeutics
Module 1: Regulatory Considerations for the Development of CNS/Neurology Therapeutics, Mondona McCann, PhD
Recorded 02/15/2024  |  90 minutes
Recorded 02/15/2024  |  90 minutes As part of your registration, you will have unlimited access to the module recording for 30 days. Your 30-day access period begins when you first access the recording. Once the access period begins, it cannot be reset or restarted. To receive a certificate of completion, you must watch the recording for the minimum required viewing time. Please keep the recording open while viewing, as the system tracks your viewing time during the active session. If you close your browser before meeting the minimum viewing requirement, your viewing progress may not be retained. Once you have met the viewing requirement, the module survey will become available. After completing the survey, you will be able to access and download your certificate of completion. If you have any questions, please contact ACT Headquarters at [email protected].
Survey
13 Questions
13 Questions ACT values your feedback. Please help us continue to provide high-quality educational offerings by completing this short survey. The survey will become available after you have met the minimum viewing requirement for the recording. Once you complete the survey, your certificate of completion will become available on your dashboard or for download.
Certificate
No credits available  |  Certificate available
No credits available  |  Certificate available Your certificate of completion will be available for download after you have met the minimum viewing requirement for the recording and completed the module survey.